



**UCI 09-17** Biology of Human Melanocytes and Keratinocytes (Meyskens)  
**UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)  
**UCI 16-01** (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

## Epidemiologic/Correlative

## Prevention

**UCI 14-92**  
Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

# Skin CA & Melanoma

## Therapeutic

**UCI 16-96**  
Ph 1 Study of RET Inhibitor, BLU-667, in Patients w/ Thyroid Cancer, NSCLC & Other Adv Solid Tumors (Ou)

**UCI 16-45**  
Ph I/Ib Safety & Efficacy Study of RP6530, a Dual PI3K  $\alpha/\beta$  inhibitor, for Relapsed/Refractory TCL (Pinter-Brown)

**UCI 16-46**  
Ph 1 MRG-106 Safety/Tolerability/PKs Study After Intratumoral/Subcutaneous/IV Injection for CTCL, MF (Pinter-Brown)

**ECOG-EAY131**  
Molecular Analysis for Therapy Choice (MATCH) (Seerv)

**UCI 16-92**  
Ph III Study of Atezo+Cobi+Vem vs Placebo+Cobi+Vem in Prev Untreated BRAFv600 Pos Melanoma (Fruehauf)

**UCI 16-102\*\***  
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

**UCI 17-09\*\***  
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (Fruehauf)

**UCI 17-73\*\***  
Effects of Encorafenib w/ Binimetinib on Losartan/etc Cocktail and on Rosuvastatin in BRAF V600-mut (Fruehauf)

**SWOG S1609**  
(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**UCI 17-50\*\***  
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**UCI 17-58\*\***  
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

## Screening/Diagnostic

**UCI 11-30** Skin imaging with Technologies in Development (Kelly)  
**UCI 14-05** Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)  
**UCI 13-13** Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)  
**UCI 15-08** Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)  
**UCI 16-82** DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4  
**UCI 16-37\*\*** Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)